Navigation Links
King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion
Date:11/24/2008

tendered and not withdrawn pursuant to the tender offer.

"We are excited about the combination of King and Alpharma, which will create a leading specialty pharmaceutical company with greater scale and capabilities," stated Brian A. Markison, Chairman, President and Chief Executive Officer of King. "Together, we will be better positioned to deliver superior value to our stockholders and significant benefits to employees of both companies. In addition, the transaction will create a stronger platform to deliver innovation to our customers. King and Alpharma are highly complementary and we look forward to even greater success as a combined company."

"The transformation of Alpharma over the past two years has created tremendous shareholder value, and we have consistently said that we will act in the best interest of shareholders," commented Dean Mitchell, Alpharma's President and Chief Executive Officer. "Therefore, after careful evaluation, our Board determined that a combination with King is in the best interest of our shareholders and provides them immediate access to this value. We believe the combined company has a compelling strategic logic and will create a strong company for both shareholders and employees. We look forward to working with King's team to integrate our companies."

King noted that Alpharma's Animal Health division will increase the diversification of King's business and is expected to provide steady cash flow to fuel future strategic initiatives, much like its Meridian auto-injector franchise. Additionally, King believes the strong commercialization capabilities that this combination provides will enhance the anticipated launches of REMOXY(R) (long-acting oral oxycodone) and EMBEDA(TM) (morphine sulfate extended-release with sequestered naltrexone hydrochloride), both of which are designed to resist or deter common methods of opioid misuse and abuse. Commercialization of these produc
'/>"/>

SOURCE King Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the Presidents Council on Physical Fitness and Sports, to Board of Directors
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
4. Keryx Biopharmaceuticals Receives Nasdaq Notification
5. Purdue Pharma L.P. Announces a Global Strategic Alliance With Infinity Pharmaceuticals to Advance Discovery and Development Programs in Oncology and Neuropathic Pain
6. FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
7. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
8. MiddleBrook Pharmaceuticals Reports Third Quarter 2008 Financial Results
9. MAP Pharmaceuticals Reports Third Quarter of 2008 Financial Results
10. Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit
11. Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... A July 9 article from USA Today ... years, according to the American Dental Association. According to a study by the American ... 1.1 million in a single year to 2.2 million a year. Dentists and ADA ...
(Date:8/3/2015)... ... August 03, 2015 , ... Illinois Health & Science (IHS) has completed ... The acquisition includes all of IBAM NA’s cyclotron sites and research and development facilities. ... regionally located business, as well as a large manufacturing hub in Noblesville, Indiana,” said ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Constantin Vasilica, 48 ... by tissue injury caused by diabetes after many years of suffering and using medications ... and he didn’t want to ask for extra time off or wait longer hours ...
(Date:8/3/2015)... (PRWEB) , ... August 03, ... ... (EMSI), a leading provider of medical information, risk management and investigative services, ... evolution and direction toward focused, expert information solutions that improve business outcomes ...
(Date:8/3/2015)... ... August 03, 2015 , ... Recent reports by the American Medical ... least once in their lives. Often time, low back and sciatic pain can happen ... only be managed clinically with powerful pain medication or spinal surgery. Dynamic Health ...
Breaking Medicine News(10 mins):Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:Dynamic Health Care in Louisville, KY, Offers a New and Cutting-Edge Therapy for Low Back & Leg Pain Sufferers 2
... Sept. 10 Birner Dental Management Services, Inc. (Nasdaq: ... dental practices announced its regular quarterly dividend. The Company,s ... cents per share of common stock. The dividend is payable ... , Birner Dental Management Services, Inc. acquires, develops, ...
... , MENLO PARK, Calif., Sept. 10 ... today announced that new research on nicotine dependence is featured ... and Endophenotypes: Foundations for Genetic Studies of Nicotine Use ... Center for Health Sciences, was the senior scientific editor of ...
... , QUINCY, Mass., Sept. 10 ... flu shots as part of its Health & Wellness initiative in ... during the cough and cold season . This year, Stop & ... Stop & Shop card holders in the pharmacy department beginning Friday, ...
... rare and dangerous disease, new laboratory research at The University ... lead researchers toward clues in more common diseases, including highly ... in the Sept. 11 issue of the journal Molecular ... damage sites is controlled by replication in both FA and ...
... 10, 2009 When a terrorist bomb explodes, a ... region, or wildfires ravage homes and businesses, plastic surgeons ... But they should be, UT Southwestern Medical ... September issue of Plastic and Reconstructive Surgery . ...
... RESTON, Va.SNM applauds the U.S. Food and Drug Administration,s ... Zevalin, as a front-line treatment of non-Hodgkin,s lymphoma ... with non-Hodgkin,s lymphoma," said Michael M. Graham, M.D., Ph.D., ... the University of Iowa Carver College of Medicine. "We,ve ...
Cached Medicine News:Health News:SRI International's Research on Nicotine Use and Dependence Featured in the National Cancer Institute's Tobacco Control Monograph Series 2Health News:SRI International's Research on Nicotine Use and Dependence Featured in the National Cancer Institute's Tobacco Control Monograph Series 3Health News:Stop & Shop To Offer Seasonal Flu Shots 2Health News:Stop & Shop To Offer Seasonal Flu Shots 3Health News:Replication at DNA damage sites highlights Fanconi anemia and breast cancer proteins 2Health News:Plastic surgeons should be part of disaster relief planning, response 2Health News:Plastic surgeons should be part of disaster relief planning, response 3Health News:SNM applauds FDA's decision to approve Zevalin 2
(Date:8/3/2015)... 2015  Encision Inc. (PK:ECIA), a medical device company ... burns in minimally invasive surgery, today announced financial results ... 30, 2015. The Company posted quarterly net ... of $213 thousand, or $(0.02) per share. These results ... net loss of $202 thousand, or $(0.02) per share, ...
(Date:8/2/2015)... LONDON , August 3, 2015 ... Dechra Pharmaceuticals PLC ("Dechra" or the "Company") ... share purchase agreement ("SPA") with Mr. Marijan Han ... voting rights) in Genera d.d. ("Genera"), a Croatian listed ... (HRK179.60) per share, which is equivalent to €51.4 million ...
(Date:7/31/2015)... -- More than 1,500 substance abuse prevention and treatment ... Indianapolis Aug. 2-6 for Community Anti-Drug ... . The week-long training, held at the JW Marriott, ... nation,s biggest public health challenges – youth drug use. ... one-of-a-kind intensive training opportunity, offering more than 70 half-day ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 2Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 5Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2
... Immunomedics, Inc. (Nasdaq: IMMU ) , ... to treat cancer and other serious diseases, today ... Cancers Symposium showed that labetuzumab-SN-38, an antibody-drug conjugate, ... animal models as an effective new therapy. ...
... Fla., Jan. 19 A new approach to unblocking ... down time, lower costs and less risk overall, particularly ... the 21st annual International Symposium on Endovascular Therapy (ISET). ... over bypass surgery to open their blocked arteries. New ...
Cached Medicine Technology:Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer 2Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer 3Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries 2
... Ultralight Jarrod Goggles have set the ... Nonslip soft silicone saddle nose bridge. ... better and lasts longer. Adjustable elastic ... without breakable plastic strap clips. 0.75 ...
QualCraft™ Radiation-Reducing Eyewear is 50% lighter than other protective eyewear. Manufactured for the ultimate combination of comfort, function, and protection....
QualCraft™ Radiation Protection Eyewear providex maximum comfort and eye protection! Lenses made of 0.75 mm leaded glass. Side shields of 0.30 mm leaded acrylic help seal out scatter radiation ...
Portable shields for your safety and convenience....
Medicine Products: